Liraglutide attenuate central nervous inflammation and demyelination through AMPK and pyroptosis‐related NLRP3 pathway

AIMS: Multiple sclerosis (MS) still maintains increasing prevalence and poor prognosis, while glucagon‐like peptide‐1 receptor (GLP‐1R) agonists show excellent neuroprotective capacities recently. Thus, we aim to evaluate whether the GLP‐1R agonist liraglutide (Lira) could ameliorate central nervous...

Descripción completa

Detalles Bibliográficos
Autores principales: Song, Shuang, Guo, Ruoyi, Mehmood, Arshad, Zhang, Lu, Yin, Bowen, Yuan, Congcong, Zhang, Huining, Guo, Li, Li, Bin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8841291/
https://www.ncbi.nlm.nih.gov/pubmed/34985189
http://dx.doi.org/10.1111/cns.13791

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8841291/
https://www.ncbi.nlm.nih.gov/pubmed/34985189
http://dx.doi.org/10.1111/cns.13791

Ejemplares similares